Balaxi Pharmaceuticals Q4 FY26 Results: Net Profit Rs 514.69 Crore, Revenue and Key Financial Highlights
- June 8, 2026
- Posted by: Kashish Aggarwal
- Category: News
Balaxi Pharmaceuticals Q4 FY26 results were declared on May 28, 2026. The company reported net profit of Rs 514.69 crore for the quarter ended March 31, 2026. Revenue from operations details are available in the BSE/NSE audited filing. Balaxi Pharmaceuticals is a Pharmaceutical Distribution and Exports company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Balaxi Pharmaceuticals Q4 FY26 Financial Highlights
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations (Rs Cr) | BSE Filing | Prior Year | See BSE/NSE filing |
| Net Profit (PAT) (Rs Cr) | 514.69 | Prior Year | See BSE/NSE filing |
| Reporting Basis | Standalone / Consolidated (see BSE/NSE filing) | ||
Data sourced from company filings and public disclosures. Always verify from BSE/NSE audited filings before investment decisions.
Balaxi Pharmaceuticals Q4 FY26 Performance Analysis
The Balaxi Pharmaceuticals Q4 FY26 results reflect performance in the January to March 2026 quarter. Revenue details are available in the BSE/NSE audited filing. Net profit of Rs 514.69 crore reflects the company operational performance. Balaxi Pharmaceuticals operates in the Pharmaceutical Distribution and Exports sector.
India macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth above 6.5%, government capex of Rs 11.21 lakh crore for FY27, and the RBI accommodative policy stance. The Pharmaceutical Distribution and Exports sector benefited from these structural tailwinds during the January to March 2026 quarter.
Key Business Factors in Q4 FY26
Revenue and Volume Performance
Revenue details for Balaxi Pharmaceuticals Q4 FY26 are available in the BSE/NSE audited filing declared May 28, 2026. The Pharmaceutical Distribution and Exports sector benefited from India domestic demand recovery and infrastructure push in FY26.
Profitability and Margin Trajectory
Q4 FY26 net profit of Rs 514.69 crore demonstrates the company performance.
Sector and Macro Backdrop
India macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI accommodative policy stance. The Pharmaceutical Distribution and Exports sector benefited from these structural tailwinds during the quarter ended March 31, 2026.
FY27 Outlook
Following the Balaxi Pharmaceuticals Q4 FY26 results, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and business strategy. India GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Balaxi Pharmaceuticals in FY27.
Balaxi Pharmaceuticals Stock Performance
Download the Univest iOS App or Univest Android App to track live price and daily stock recommendations.
Shares of Balaxi Pharmaceuticals are listed on NSE and BSE. Following the Q4 FY26 results on May 28, 2026, investors should monitor post-results price action and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.
Key Risks
Revenue and Demand Risk
Any deceleration in India GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Balaxi Pharmaceuticals products and services in the Pharmaceutical Distribution and Exports sector in FY27.
Margin and Cost Volatility
Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks. Any cost escalation without corresponding pricing power could compress profitability.
Conclusion
Balaxi Pharmaceuticals Q4 FY26 results declared on May 28, 2026 showed net profit of Rs 514.69 crore. Investors should monitor management guidance and sector trends before making investment decisions.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE/NSE audited filings.
Frequently Asked Questions on Balaxi Pharmaceuticals Q4 FY26 Results
What is Balaxi Pharmaceuticals Q4 FY26 net profit?
Ans. Balaxi Pharmaceuticals Q4 FY26 net profit was Rs 514.69 crore. Results declared May 28, 2026.
What is Balaxi Pharmaceuticals Q4 FY26 revenue?
Ans. Balaxi Pharmaceuticals Q4 FY26 revenue is available in the BSE/NSE audited filing declared May 28, 2026.
When were Balaxi Pharmaceuticals Q4 FY26 results declared?
Ans. Balaxi Pharmaceuticals Q4 FY26 results were declared on May 28, 2026 at the board meeting approving audited financial statements for the quarter and year ended March 31, 2026.
What is the FY27 outlook for Balaxi Pharmaceuticals?
Ans. Following Balaxi Pharmaceuticals Q4 FY26 results, management guidance on revenue growth, margin improvement, and sector dynamics shapes FY27 expectations. Consult a SEBI-registered advisor before investing.
Is Balaxi Pharmaceuticals a good stock to buy after Q4 FY26 results?
Ans. Investment decisions require assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This content is educational only. Consult a SEBI-registered financial advisor.
What sector does Balaxi Pharmaceuticals operate in?
Ans. Balaxi Pharmaceuticals operates in the Pharmaceutical Distribution and Exports sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 28, 2026.
